Researchers assessed the risk of myocarditis or pericarditis after the COVID-19 mRNA vaccine second doses.
The comparative risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273 second doses

Specialist researcher holding microscope slide analyzing blood sample working at coronavirus vaccine development during virus examination in microbiology hospital laboratory. Biochemistry experiment
Comments